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Introduction
The disruption of endothelial homeostasis and inflammation are
fundamental to the initiation and progression of atherosclerosis
and preeclampsia (PE) [1–2]. PE is a pregnancy-specific multi-
organ syndrome characterized by widespread endothelial damage
with a clinical presentation of hypertension and proteinuria after
20 weeks of gestation [3]. It affects 3–8% of all pregnancies, with
an incidence of 0.8% before 32 weeks [4]. The WHO reports over
60,000 maternal deaths worldwide per year as a consequence of
eclampsia. Women with PE and their offspring are at an increased
risk of developing cardiovascular disease later in life [5, 6].
Defective vasculogenesis in early placentation and resultant placen-
tal ischemia have been proposed to trigger the release of unknown
mediators. Soluble anti-angiogenic factors in the maternal circula-
tion precede the clinical PE and result in systemic maternal
endothelial dysfunction [7–14]. We originally proposed that sFlt-1,
an alternative mRNA splice variant of the fms-like tyrosin kinase
gene (Flt-1) and antagonist of vascular endothelial growth factor
(VEGF or VEGF-A), might be a key factor responsible for the clini-
cal manifestation of PE because of a loss of circulating free VEGF
[15]. Indeed, cancer patients receiving bevacizumab (Avastin®,
Roche; anti-VEGF therapy) exhibit PE-like symptoms (hyperten-
sion, proteinuria), suggesting that decreased bioavailability of
VEGF causes these symptoms. Given the neurological findings in
these patients, this is in line with recent observations that VEGF
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Abstract
Preeclampsia (PE) is characterized by widespread endothelial damage with hypertension, proteinuria, glomeruloendotheliosis and 
elevated soluble Flt-1 (sFlt-1), a natural occurring antagonist of vascular endothelial growth factor (VEGF). Cancer patients receiving anti-
VEGF therapy exhibit similar symptoms. We suggested  that a decrease in circulating sFlt-1 would alleviate the symptoms associated
with PE. Adenoviral (Adv) overexpression of sFlt-1 induced proteinuria, caused glomerular damage and increase in blood pressure in
female Balb/c mice. Circulating level of sFlt-1 above 50 ng/ml plasma induced severe vascular damage and glomerular endotheliosis.
Albumin concentration in urine was elevated up to 30-fold, compared to control AdvGFP-treated animals. The threshold of kidney damage
was in the range of 20–30 ng/ml sFlt-1 in plasma (8–15 ng/ml in urine). Co-administration of AdvsFlt-1 with AdvVEGF to neutralize 
circulating sFlt-1 resulted in more than a 70% reduction in free sFlt-1 in plasma, more than 80% reduction in urine and rescued the dam-
aging effect of sFlt-1 on the kidneys. This demonstrates that below a critical threshold sFlt-1 fails to elicit damage to the fenestrated
endothelium and that co-expression of VEGF is able to rescue effects mediated by sFlt-1 overexpression.
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and transforming growth factor beta (TGF) blockage effected
choroid plexus integrity and function in adult mice [16].
We proposed earlier, that sFlt-1 may be also involved in several
other vascular diseases [17]. Previous studies from our group
indicated that the amniotic fluid from PE patients early in preg-
nancy contains elevated sFlt-1 levels [18]. sFlt-1 is increased in
the maternal circulation in PE, even before onset of the clinical dis-
ease [8, 10–13]. Despite the multiple genotypes and phenotypes
that underlie PE, it appears that serum levels of sFlt-1, placental
growth factor (PlGF) and soluble endoglin (sEng) give the highest
strength of association with outcome [7–9]. However, based on a
recent systematic review, at present the evidence is insufficient to
recommend these markers for screening [19].
Direct evidence that excess circulating sFlt-1 plays a role in the
pathogenesis of PE was provided by studies in rats where admin-
istration of sFlt-1 or a VEGF neutralizing antibody resulted in
glomerular endothelial cell damage and proteinuria [20], and ade-
noviral delivery of sFlt-1 to pregnant animals mimicked the clinical
manifestations of PE [21]. The induction of uteroplacental ischemia
in a pregnant non-human primate model resulted in the develop-
ment of clinical symptoms analogous to human PE including a sig-
nificant elevation of circulating sFlt-1 [22]. However, whether or not
a reduction of sFlt-1 by induced complex formation with the corre-
sponding ligand would alleviate hypertension, proteinuria and
glomeruloendotheliosis is unknown. Here we report that adenovi-
ral overexpression of sFlt-1 in mice induced proteinuria, caused
glomerular damage and increased blood pressure. However, when
co-administered with AdvVEGF to neutralize circulating sFlt-1, the
damaging effect of sFlt-1 on the kidneys was ameliorated when free
sFlt-1 in plasma fell by more than 70%. Thus, reduction in sFlt-1 is
a valid surrogate end-point for a clinical outcome measure.
Materials and methods
Reagents and ELISA measurements
Mouse sFlt-1 duo set kits were purchased from R&D Systems (Rüsselsheim,
Germany). The minimum detection level was about 0.3–0.6 ng/ml in plasma,
urine and in tissue lysates. ELISA for human sFlt-1 and human VEGF were
performed as described before [23–24]. ELISA for mouse sFlt-1 was per-
formed according to the manufacturer’s instructions. Briefly, the various
samples for ELISA measurements were diluted in diluents as recommended.
Liver lysates were diluted 1: 20 or 1: 200 and plasma samples were diluted
1: 10 and urine samples 1: 5. Cell culture supernatants were diluted up to 
1: 250. The diluted samples were incubated in 96-well plates precoated wit
the capture antibody directed against VEGF, human sFlt-1 and mouse sFlt-1
for 1–2 hrs. The wells were then washed three times in phosphate buffered
saline (PBS with 0.1% Tween) and incubated with a biotinylated secondary
antibody against the antigens for 1–2 hrs. The plates were than washed again
three times and incubated with streptavidin-horseradish peroxidase for
30–60 min. The plates were than washed again and incubated with substrate
solution containing H2O2 and tetramethyl benzidine (TMB Plus from
KEMENTEC Diagnostics, Denmark). The absorbance was determined at 
450 nm. All assays were done in duplicates, and the protein concentrations
were calculated using a standard curve derived from known concentrations
of recombinant protein standards. Total protein concentrations in all lysates
were calculated using the BCA assay (Pierce/Thermo, Rockford, IL, USA).
Protein concentrations in lysates were normalized to the total protein con-
centration and indicated as ng/mg total protein. 
Immunoprecipitation and Western blotting
Immunoprecipitation (IP) and Western blotting was used for the detection
of VEGF-A and VEGFR-2 (Flk-1) in cell lysates, liver lysates or kidney
lysates. For IP of VEGF-A from cell lysates and liver lysates after aden-
ovirus treatment 1–6 mg protein was incubated over 2 hr (cell lysate) or 
16 hr (liver lysates) with 1 g anti-VEGF-A antibody (MAB clone 3C5,
Reliatech, Wolfenbuettel, Germany). For pull-down lysates were supple-
mented with 50 l anti-mouse IgG agarose (Sigma) and incubated over
night at 4C. Beads were washed several times with TBST and pellet was
diluted with 4x Laemmli buffer, boiled for 5 min and cooled on ice. Twenty
l of sample were subjected to SDS-PAGE (12.5% gels) and electroblotted
onto PVDF membranes (Millipore). The membrane was blocked with 50%
low-fat milk in TBS buffer and incubated with an antigen-affinity-purified
VEGF-A antibody at 1 g/ml (#2668, Reliatech) in TBS/10% low-fat milk
overnight at 4C. To visualize the signals, the membrane was incubated
with a goat-anti rabbit IgG conjugated with horseradish peroxidase (dil. 
1: 5.000 until 1: 10.000, Promega). Signals were developed with Super
Signal West (Pierce/Thermo) or ECL system and Hyperfil ECL (GE,
Freiburg, Germany) were used for documentation. To detect VEGFR-2
(FLK-1) in cell lysats and kidney lysates a similar procedure was used. The
anti-VEGFR-2 antibody diluted 1: 100 (rabbit MAB clone 55B11, Cell
Signalling) was used for pull-down and for Western blotting (dil. 1: 1.000;
7.5% gels). For detection of VEGFR-2Tyr1175 the same antibody was used
as before for pull-down but for immunoblotting the antibody phospho-
VEGFR-2 Tyr1175 (rabbit MAB clone 19A10, Cell Signalling) was
employed. The anti-beta actin antibody was from Chemicon (MAB1501).
Animals
All experiments were performed on 10–12 weeks old female Balb/c mice
with a mean weight of 22.4 g (range 18.9 and 26.3 g) obtained from
Harlan, Germany. The animals were allowed free access to standard chow
(0.25% sodium; SNIFF Spezialitaeten, Soest, Germany) and drinking water
ad libitum. The protocol was approved by the local council on animal care
that corresponds to requirements of the American Physiological Society.
Mouse model
The preparation of the adenoviruses for mouse sFlt-1-Fc (AdvsFlt-1),
AdvVEGF165 and adenoviruses for green fluorescence protein (AdveGFP;
control) have been described before in detail [25–26]. The extracellular
domain of mouse sFlt-1 (amino acid 1–758) was fused with the mouse
immunglobulin Fc tail. A size of 130 kD of the gene product was confirmed
in cell supernatants. All virus preparations were tested in vitro and gene
products were estimated by ELISA or Western Blot as described earlier
[26] Mouse sFlt-Fc was also estimated by a Western blot using antibodies
against mouse Fc. The virus titre was estimated by an end-point dilution
assay and pure virus preparations were desalted and stored in –70C until
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used [27]. Approximately 50–100 l of virus diluted in PBS was used for
injections. Both, the pregnant and the non-pregnant Balb/c mice were
injected with AdvsFlt-1 (2.5 to 7.5  109 pfu) or AdvVEGF165 (1–2  108 pfu)
or AdveGFP (2–4  109 pfu) into the tail vein. Each treatment group existed
of 2–3 animals and all experiments were at least three times repeated (n 
6–9). In some experiments pregnant mice were injected at day 4, 8 or 9 of
pregnancy and the phenotypes were recorded 10 days later (for details see
Table 1). Initially we used non-pregnant and pregnant mice very similar as
used in a rat model before [21]. Because we could not detect significant
differences in kidney histology, all data presented in the figures are from
non-pregnant mice.
Blood samples from untreated animals were collected one week before
virus injection. Urine samples were collected in metabolic cages between
day 10 and 11 after virus treatment. After euthanasia, on day 10 or day 11
after adenoviral injection, blood samples, kidney, liver, lung and heart were
collected and frozen on dry ice or fixed with formaldehyde. Liver weight
was also documented as well as the macroscopic appearance of liver and
spleen by digital photography. Liver sFlt-1 concentration (endogenous and
exogenous concentration) as well as circulating msFlt-1-Fc and urinary
sFlt-1-Fc were quantified by ELISA as described above. We measured uri-
nary albumin by a competitive ELISA from Cell Trend GmbH (Berlin,
Germany). We used harvested livers and kidneys for histopathology and
some kidneys for electron microscopy. Lysates from liver and kidneys were
done with RIPA buffer performed with a dispersing device for homogeniza-
tion. Further lysates from livers and kidneys were also used to determine
levels of exogenously induced and endogenous proteins.
Telemetry and blood pressure measurements
The telemetric technique was described in detail elsewhere [28]. Mice were
anesthetized with isoflurane (CuraMed Pharma, Karlsruhe, Germany). The
pressure-sensing catheter of the TA11PAC20 BP device (Data Sciences
International, Saint Paul, MN, USA) was advanced via the carotid artery into
the ascending aorta, and the transmitter was placed in a subcutaneous pocket
along the right flank. The mice were synchronized to a light-dark schedule 
of 12: 12 h with lights on at 6: 00 a.m.. All mice were allowed 10–14 days
recovery from surgery before baseline blood pressure (BP) and heart rate
(HR) values were recorded for 3 days. By this time, the mice had regained
their circadian BP and HR rhythm, and the surgery and anesthesia-dependent
initial changes in systolic blood pressure (SBP), diastolic blood pressure
(DBP), mean arterial blood pressure (MAP) and HR were followed by stable
values. Directly after injecting adenoviruses into the tail vein data sampling
was continued. All data from TA11PA-C20 device were sampled every 5 min
for 10 sec continuously day and night with a sampling rate of 1000 Hz and
stored on a hard disk. The BP measurements were conducted over a period
of 10 days after virus application. SBP, DBP and HR were recorded using the
DATAQUEST software (A.R.T. 2.1; Data Sciences International). HR was com-
puted from the pulse intervals of the BP recordings.
Histology and electron microscopy
The kidneys of all animals used in this study (n  300) were examined
histopathologically. Freshly excised kidneys were immersion-fixed in neutral
buffered 10% formalin, paraffin embedded, sectioned at 5 m thickness
and stained with hematoxylin and eosin (HE) as well as by PAS reaction.
Glomerular lesions were analysed in at least 10 glomeruli of the inner 
cortex region per animal and were examined for endothelial swelling,
occlusion of capillary loops and protein resorption droplets. For electron
microscopy, renal tissues were fixed according to Karnovsky, pre-con-
trasted with 1% osmium tetroxide, dehydrated in 70% ethanol containing
1% uranyl acetate and 0.5% phosphotungstic acid and embedded in
epoxid resin. Sections of 30 to 50 nm thickness were contrasted with lead
citrate and examined using a Zeiss 900 transmission electron microscope.
Immunohistochemistry
Immunohistochemistry was performed on serial frozen or formaldehyde-
fixed wax-embedded sections as described previously [29]. Briefly, cryo-
stat sections were fixed in acetone at –20C for 20 min, endogenous per-
oxidase activity was neutralized with 0.3% (v/v) H2O2 in methanol for 15 min
and blocked with 10% normal serum in PBS for 20 min. Sections were
incubated with primary antibody for 1 hr at room temperature. Non-
immune goat serum was substituted for the primary antibody as a nega-
tive control. After washing in PBS, sections were incubated with a 1: 1.000
dilution of the appropriate biotinylated secondary antibodies (Vector
Laboratories, Ltd., Peterborough, UK) for 30 min and then streptavidin-
peroxidase complex (Vector Laboratories) for 30 min. Staining was visual-
ized using diaminobenzidine (Dako UK, Ltd., Cambridgeshire, UK) and 
sections were counterstained with haematoxylin.
Albumin measurements and protein 
silver staining in urine samples
Visualization of total proteins was carried out by protein gel electrophoresis.
Therefore, 1.0 l of urine from treated or untreated mice was placed in 11 l
Laemmli buffer, boiled and loaded on a 10% SDS-PAGE gel. An SDS-PAGE
broad-range standard (protein ladder, Fermentas, Germany) was loaded on
the first lane on the gel and bands were visualized by silver staining.
Day Normal / rescue Blood pressure Pregnant
14 Implant. of transp.
10 coll. blood
0 inj. AdV inj. AdV Mating of mice
4 d4 of pregn: inj. AdV
5 d5 of pregn: inj. AdV
8 d8 of pregn: inj. AdV
10 End End
14/ 15/ 18
End (d14, d15, d18
of pregn.)
Table 1 Study protocol
Conduction of different experiment groups is shown. Blood was col-
lected 10 days before start and at the end of the experiment. Implant. of
transp. -implantation of transponder; coll. blood - collection of blood for
plasma preparation; inj. AdV - injection of recombinant adenoviruses;
d4 of pregn. - day 4 of pregnancy; end- end of the experiment. At the
end of every experiment blood (urine if possible) was collected, mice
were killed and kidney and liver harvested and stored at –70°C.
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Statistics
The mean and standard error were calculated on most of the parameters
determined in this study. Data are given as mean 	 SEM. ANOVA was used
to determine statistical differences. Significant differences are reported
when P 
 0.05.
Results
Soluble Flt-1 induces histological changes 
in mouse kidneys
As reported earlier, adenovirus-vector-mediated overexpression of
sFlt-1 in pregnant rats led to the formation of renal damage indi-
cated by glomerular endotheliosis, proteinuria and hypertension
[21]. To establish a mouse model we started to inject AdsFlt-1
from 1  106 pfu until 2  1010 pfu into the tail vein.
Most of the doses either had no effect on the kidney histology
( 1  109 pfu) or were lethal within the 10 day time course 
( 7.5  109 pfu). However, injection of AdsFlt-1 between 2.5 and
3.5  109 pfu-induced moderate histochemical changes in the
glomeruli and doses between 5 and 7.5  109 pfu-induced severe
histological changes including severe endotheliosis and occlusion
of capillary lumens (Fig. 1A). No significant changes in morphology
were detected in AdveGFP-treated or untreated animals 
(Fig. 1A). Electron microscopy revealed that endothelial cells and
podocytes were both affected in sFlt-1-treated animals (Fig. 1B).
Capillary lumens were occluded by microthrombi, endothelial cells
were detached from the basal membrane and macrophages were
present in thrombotic regions. In addition, macrophages as foam
cells could be seen and podocytes showed segmental effacement
of foot processes (Fig. 1B). Furthermore, fragmented erythrocytes
Fig. 1 Renal histology in mice either untreated or after treatment with AdvGFP or AdvsFlt-1. (A) Renal histology in mice after GFP (control) and sFlt-1
groups. Untreated and eGFP-treated mice show no glomerular changes. Low-dose soluble Flt-1- (2.5  109 pfu  L) injected mice develop moderate
swelling of glomerular endothelial cells and mesangial cells with limited occlusion of the glomerular capillary lumen. In contrast, high-dose soluble Flt-
1- (7.5  109 pfu  H) injected mice show severe occlusion of glomerular capillary lumen. H&E hematoxylin and eosin stain; PAS periodic acid Schiff
reaction; scale bar 50 m (B and D). Transmission EM of the ultra structure in untreated and sFlt-1-treated mice demonstrated regular foot processes
of podocytes and missing of endothelial fenestration after treatment. Ten days after treatment (d) podocytes and endothelial cells are affected and
microthrombi can be found in the former capillary lumen. Foot processes are partly regular and partly effaced.; P  podocyte, EC  endothelial cell,
arrow  basal membrane, * deposit of microthrombi inside of vessel lumen, bar  1 m; (C and E) Masson Goldner stain indicates intact erythrocytes
(bright red) in the glomerulus of untreated mice (C) and fragmented erythrocytes inside the glomeruli of sFlt-1-treated mice (E).
J. Cell. Mol. Med. Vol 14, No 6B, 2010
1861© 2009 The Authors
Journal compilation © 2010 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
and microthrombi were seen after Masson Goldner staining as well
as the lack of fenestrated endothelium (Fig. 1C). Although the ery-
throcytes were restricted to capillary loops as observed in
untreated animals, fragmented erythrocytes accompanied by ery-
throcyte dust were widespread in the glomeruli of treated animals.
This characteristic glomerular lesion represents a form of glomeru-
lar endotheliosis, the thrombotic microangiopathy. Nevertheless,
the mice appeared healthy after a 10 days treatment period and
showed no unusual behaviour, making cerebral involvement
unlikely. As stated before, some single experiments were also
made with pregnant mice. Injection early in pregnancy (e.g. day 4
of pregnancy) resulted either in termination of pregnancy or in
strong retarded embryos whereas injections late in pregnancy (day
8 or 9) had macroscopically no effect on the appearance of the
embryos (not shown). Even if not investigated in a detailed way,
early treatment seems to have a strong negative effect on vascular
placental development. However, the high heterogeneity of the
results prompted us not to investigate changes in more detail.
Effects mediated by sFlt-1 can be rescued 
by VEGF co-administration
Complex formation between VEGF and sFlt-1 to reduce the
bioavailability of VEGF is an important regulatory mechanism to
maintain angiogenic balance and is responsible for the avascular
cornea in mammals [30].
The pathological effect mediated by sFlt-1 treatment (3.5 
109 pfu) could be rescued by injection of 1  108 VEGF-encoding
virus particles at the same time when sFlt-1 was injected (Fig. 2).
Higher sFlt-1 doses had not been tested for combinations.
Compared to the sFlt-1 virus amount, this dose seems to be very
low. However, double that concentration of Adv has been shown
before to be lethal in mice and we were able to confirm it exactly
[31]. Our observation also indicates that the almost maximum tol-
erable VEGF amount was induced in the mouse model and that
both groups had used a similar bioassay to determine the titre of
the virus preparations. Strikingly, the histological analysis of
glomeruli of mice administered both viruses was similar to control
mice, indicating a significant improvement in capillary patency, a
reduction of deposits and endothelial swelling (Fig. 2).
Subendothelial accumulation of fibrin and albumin characterizes
severe endothelial damage and is associated with rapid loss of
renal function. sFlt-1-treated rats showed focal deposition of 
fibrin within glomeruli [21]. Similarly, AdvsFlt-1-treated mice
showed an increase in fibrin and albumin immunostaining in the
glomeruli, while AdvVEGF alone treated animals showed no fibrin
and albumin (Fig. 2). However, coinfection with AdvsFlt-1 and
AdvVEGF produced a marked reduction in expression of albumin
and fibrin when compared to AdvsFlt-1-treated mice (Fig. 2).
Fig. 2 Renal histology in rescue mice.
Renal histology in mice after VEGF (1 
108 pfu) and sFlt-1 (3.5  109 pfu) treat-
ment, and in sFlt-1VEGF groups.
VEGF-treated mice show no significant
lesions. Soluble Flt-1-injected mice
show severe endotheliosis with occlu-
sion of capillary lumens. Soluble Flt-1 
VEGF-treated animals show mild effects
of glomerular endotheliosis and much
less accumulation of fibrin and albumin
seen in sFlt-1-treated animals. HE
haematoxylin and eosin stain, PAS peri-
odic acid Schiff reaction; IHC for fibrin
and albumin was counterstained with
haematoxylin; scale bar 50 m.
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Quantitative measurements of sFlt-1 in plasma indicated that
the circulating concentration was lowered from 32 	 15,9 ng/ml
to about 10.6 	 3,4 ng/ml (Fig. 3A) in rescued mice. A similar
decrease was found in 24-h urine of treated animals. Here, the
detectable concentration was 8 	 0,6 ng/ml and declined to 1.3 	
1,8 ng/ml in co-treated animals. Injection of high-dose sFlt-1 led
to concentrations of 79 	 29,6 ng/ml in plasma and 36.9 	 25,6
ng/ml in urine when measured by sandwich ELISA (Fig. 3B).
However, the highest sFlt-1 concentrations were found in liver
 tissue, which ranged between 200 and 1000 ng/mg total protein
(data not shown). Interestingly, in AdvsFlt-1-treated mice, the con-
centration of total sFlt-1 protein in the kidney (endogenous and
exogenous) was more than tripled, compared to untreated animals
(87,7 	 4,5  ng/mg total protein versus 26.1 	 16,3 ng/mg total
protein, data not shown). The concentrations detected in plasma
were similar to recent rat and mouse models where AdV have been
used for sFlt-1 overexpression [21, 32–33]. However, the concen-
trations in our mouse model were about 10-fold higher than the
Fig. 3 Quantitative measurement of mouse sFlt-1 by ELISA and detection of VEGF-A and VEGF-R in mice. In mice either untreated (n  4) or treated
with Adv for eGFP (n  4) or AdvVEGF (n  6) endogenous sFlt-1 concentrations are under the detection level in plasma (A) and in urine (B). Mice
treated with high concentrations of Adv for sFlt-1 (5–7,5  109 pfu, n  10) show extremly high concentrations and mice treated with lower levels,
which were also used for rescue experiments (2,5–3,5  109 pfu, n  10) have a reduced level for sFlt-1 in plasma and urine. Rescue experiments with
AdsFlt-1 and AdVEGF (1  108, n  4) have significant reduced levels in plasma und urine. Data are mean (	SEM) of several mice used for each exper-
iment. *P 
 0.05 as compared with low-dose sFlt-1- (AdsFlt-1- L) treated mice. Representative detection of VEGF-A (C) and VEGFR-2/FLK-1 (D) in 
adenovirus-treated cells and mice by reducing Western blot. To detect VEGF-A 1 mg cell lysates was used for IP. For IP from kidney lysates 5 mg total
protein was immunoprecipitated with an anti-VEGF-A monoclonal antibody. As positive control 5 ng rh VEGF-A (isoform 165 from insect cells) was used
directly. For sample loading beta-actin was detected by immunoblotting for the same blot with an appropiate antibody. To detect the VEGFR-2/Flt-1 total
protein or the phosphorylated protein, 20 g cell lysates from mouse endothelial cells either unstimulated or stimulated with VEGF-A (50 ng/ml over
10 min) was loaded directly on the gel. For IP from kidney lysates 2 mg of total protein was immunoprecipitaed with an anti-mouse VEGFR-2 antibody
and immunoblotted with the same antibody. For detection of phosphorylated mouse VEGFR-2 400 g cell lysates and 4 mg kidney lysates were used
for IP followed by immunoblotting with an antibody for phospho-VEGFR-2-Tyr1175. For sample loading beta actin was detected by using 40 ug lysates
from each samples for immunoblotting with an appropiate antibody.
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concentrations found in patients with severe PE but taken into
account, that the concentrations were measured with different
assays for human and mouse sFlt-1 [8,21].
Verifying VEGF-A overexpression in mice 
and changes of VEGFR-2 levels in kidneys
To verify the overexpression of VEGF-A by adenovirus treatment
we used infected cell lysates and liver lysates from Adv VEGF-
treated animals together with immunprecipitation and
immunoblotting. In infected cells, two bands between 22 and 
24 kD corresponding to unglycosylated and glycosylated VEGF-
A were found (Fig. 3C). Liver lysates from Adv VEGF-A-treated
mice show a significant higher amount of exogenous VEGF-A
and only the full glycosylated protein can be detected.
Endogenous VEGF-A was detected in minor amounts in the liver
(Fig. 3C). Based on the structural changes of the capillaries
observed in the glomerulus, we were further interested to find
out, if the structural changes influenced the amount of VEGFR-
2/Flk1 in the whole kidney or if the phosphorylation status of the
receptor molecule is changed in this organ after treatment with
antagonists. The detection of VEGFR-2 by IP and immunoblot-
ting was straight forward in mouse endothelial cells. Two bands
of about 210 and 230 kD can be found where the larger bands
represent the full glycosylated molecule. Stimulation of these
cells after starvation with VEGF-A over 10 min leads to phospho-
rylation of the 230 kD receptor protein, verified by an antibody
specific for phospho Tyr1175 of VEGFR-2. No significant
changes of the receptor protein amounts were observed after
different adenoviral treatment of mice. However, mice treated
with Adv VEGF-A show a down-regulation of VEGFR-2 as a result
of VEGF-A overexpression in the animal. No receptor down-
 regulation was observed in mice co-treated with Adv sFlt-1 and
VEGF-A. Further, we were not able to detect phosphorylated
VEGFR-2 in kidney lysates with our antibodies. Confirmation of
phosphorylated VEGFR-2 in kidney lsates resulted merely in
unspecific bands although immediately shock-frozen tissue was
used. Probably the used antibodies were not able to detect phos-
phorylated VEGFR-2 in our kidney lysates.
Glomerular function can be changed 
by sFlt-1 and sFlt-1/VEGF treatment
Mice treated with high and low doses sFlt-1 had heavy albumin-
uria (Fig. 4A), but not control mice. Co-treatment with AdvVEGF
and AdvFlt-1 inhibited proteinuria, as indicated by polyacrylamide
gel electrophoresis and silver staining of 24-h urine. In these res-
cued mice, the albumin concentration was reduced from 15.6 	
3,0 mg/ml to 0.13 	 0,05 mg/ml (Fig. 4B), a reduction to the
range of control animals. In addition, the albumin creatinine ratio
determined in control animals, sFlt-1-treated and VEGF/sFlt-1-
treated animals. Low dose sFlt-1-treated animals had a urine
albumin/creatinine ratio of about 49,2 	 3,3 mg/mg. However,
VEGF-co-treated showed a ratio of only 0,27 	 0,04 mg/mg,
which was very similar to untreated animals that were in the
range of 0,15 mg/ml (data not shown).
Fig. 4 Functionality of glomerular filtration of sFlt-1-treated mice after a
10 days time period. (A) SDS-PAGE analysis was performed with 1 l of
representative mouse urine samples. Lane 1 contains urine from
untreated mice, lane 2 urine from eGFP mice (2  109 pfu) and lane 3
shows urine from mice treated with Adv for VEGF (1  108 pfu). Lane 4
and 5 contain urine from mice treated with AdvsFlt-1 (7,5  109pfu (H)
and 3.5  109 pfu (L), respectively) and lane 6 urine from a rescue exper-
iment. The presence of large amounts of albumin around 67 kD is identi-
fied in the AdvsFlt-1-treated mouse and demonstrated damage of the kid-
ney filter. (B) Mouse albumin was measured by ELISA in 24-h urine from
untreated (n  6), GFP (2  109 pfu, n  2), VEGF (1  108pfu, n  3)
and msFlt-1- (3,5  109 pfu, n  3) treated animals. For rescue mouse
were co-treated with msFlt-1 and VEGF (n  2). Data are mean (	SEM)
of several mice used for each experiment. *P 
 0.01 as compared with
sFlt-1- (AdsFlt-1) treated mice.
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Effects of sFlt-1 overexpression in the absence
and presence of VEGF on blood pressure
Hemodynamic effects following AdvsFlt-1 injection or after co-
treatment with AdvVEGF and AdvsFlt-1 was monitored using
telemetry. Injection of adenovirus for eGFP (2  109 pfu) had
almost no effect on the heart rate but led to a decrease in SBP
(–5 mm Hg) and DBP (–16 mm Hg) that normalized after several
days (Fig. 5). Overexpression of sFlt-1 resulted in significant
increases in SBP (149 versus 130 mm Hg) and DBP (119 versus
100 mm Hg), compared to the eGFP-treated animals before virus
injection. Co-administration of AdvsFlt-1 and AdvVEGF led to an
initial sharp decrease in heart rate and reduction of blood pres-
sure (Fig. 5) for the first 2 days and returned thereafter to base-
line values (SBP 122 versus 125; DBP 93 versus 101). The sharp
decrease in blood pressure was probably because of the effect of
VEGF, which is also a potent hypotensive factor [34–35]. There
probably was an initial excess of free VEGF in the circulation,
which was later complexed with the corresponding receptor and
led to normal heart rate and blood pressure. These results are in
agreement with the histology and proteinuria data we analysed
from rescue experiments.
In vitro complex formation 
between VEGF165 and sFlt-1
Measurements to quantify free VEGF either by our own ELISA or
with a commercial ELISA (R&D Systems) in the serum of VEGF-
treated mice were not successful probably because of the low half
life during circulation and the low amount of free VEGF (data not
shown). However, complex formation by the decrease of
detectable sFlt-1 by VEGF co-expression could be easily shown in
vitro with A549 cells. Soluble Flt-1 concentrations in the super-
natant which could be measured by ELISA decreased between
70% and 80% when VEGF was co-expressed in low amounts (Fig.
6). Furthermore, sFlt-1 measurements of complementary cell
lysates verified observations made in the supernatant of co-
infected cells (not shown). These results indicated, that the lower
amounts of sFlt-1 detected in Adv co-treated animals were
because of the inability of the ELISA’s to detect complexed (lig-
anded) sFlt-1.
Fig. 5 Representative recordings of heart rate and systolic/diastolic blood pressure. The injection time-point of adenoviruses is indicated by a vertical
line on the time axis. Recording of data was estimated for 8–10 days after treatment. Side a shows the treatment with AdveGFP (2  109 pfu), side b
with AdvsFlt-1 (3  109 pfu) and side c shows the co-treatment with AdvsFlt-1 (3  109 pfu) and AdvVEGF (1  108 pfu) for rescue experiments.
Indicated is the heart rate (HR) in beats per min (BPM, upper panel) and the systolic (SBP, lower panel, upper graph) and diastolic (DBP lower panel,
lower graph), blood pressure in mm Hg.
Fig. 6 ELISA quantification of in vitro complex formation between 
sFlt-1-Fc and VEGF in cell supernatants. Five hundred fifty-nine cells were
infected with increasing amounts of Ad-sFlt-1in the absence (white bars)
or in the presence of Ad-VEGF with a MOI of 10 (grey bars) or with MOI
of 20 (black bars). The amounts of sFlt-1 in the supernatant 72 hrs after
infection were diluted and measured by an ELISA for mouse Flt-1.
Indicated are the mean values from duplicates (mean 	 SEM).
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Discussion
This study demonstrates that infection of non-pregnant and preg-
nant mice with adenovirus carrying mouse sFlt-1 leads to an
increase in circulating levels of sFlt-1 followed by albuminuria and
hypertension. We further show that co-administration of AdvsFlt-1
with AdvVEGF neutralizes circulating free sFlt-1 and the damaging
effects of sFlt-1 on the kidneys are ameliorated and blood pressure
normalized. Previous reports in human beings suggested that
 perturbation in free VEGF and PlGF plasma levels weeks before 
the clinical onset and manifestation of PE, point to a systemic
endothelial dysfunction and a possible mechanism [7–8].
However, according to our working hypothesis, blocking of VEGF
and PlGF bioavailability at local sites of paracrine and autocrine
loops are the primary cause of endothelial dysfunction. The circu-
lating levels of VEGF and PlGF were significantly lower than the KD
of VEGFR-1 and -2, and therefore should not have had the
observed biological effects [36–37]. For example, free VEGF
declined from about 0.3 pM to 0.14 pM in women with clinical PE,
wheras the KD of VEGFR-2 was calculated with 760 pM [8, 36].
However, our results in combination with previous reports in rat
and mouse by Maynard et al. [21] and Lu et al. [33] strongly sup-
port a causative role for sFlt-1 in endothelial dysfunction, either
primary or intermediary.
We used classical adenovirus vectors that express sFlt-1 and
VEGF, either separately or in combination. Because of vector tro-
pism, such vectors will be sequestered primarily in the liver when
injected [38]. This fact was nicely demonstrated by our ELISA
measurements of liver samples, where up to 0.1% of the liver
total protein was sFlt-1. However, the high serum and urine level
of sFlt-1 (Fig. 1C) suggested that the delivered adenoviruses
effectively transduced murine liver cells that subsequently
secreted sFlt-1 and VEGF into the systemic circulation. As a mat-
ter of fact, the amount of total Flt-1 (endogenous and exogenous)
almost tripled in the kidney after 10 days of treatment. In another
model of endothelial dysfunction and crescentic glomeru-
lonephritis, rats were treated with antibodies for antiglomerular
basement membranes and then transfected with plasmid DNA
encoding the murine sFlt-1 gene into the femoral musculature
[39]. Here, sFlt-1 accelerated the progression of glomerular scle-
rosis and interstitial fibrosis during a 56-day time course. The
effects observed by the additional sFlt-1 transfection were mild
compared to our model. Also sFlt-1 concentrations in the urine
after 6-days of treatment from about 0.2 ng/ml were 50–100-fold
lower than our concentrations [39]. However, over a longer time
course, VEGF inhibition in this model accelerated glomerular and
peritubular endothelial loss.
Ideally, conditional expression of sFlt-1 in placental tro-
phoblasts in pregnant mice induced in the last trimester of the
pregnancy would be the best experimental model. Therefore, over-
expression of sFlt-1 in the liver does not mimic the development
of PE. In our mouse model, complex formation of VEGF with its
corresponding soluble receptor takes place in liver cells or in the
circulation. This situation is different from human PE, where sFlt-1
is produced by cytotrophoblasts and enters the maternal circula-
tion and tissue compartments [21]. This site is probably the place
where dimerisation takes place. Complex formation between VEGF
and excess sFlt-1 and blocking the loss of endogenous VEGF can
be also initiated by administration of recombinant VEGF121. This
fact was shown very recently in a rat model with adenoviral over-
expression of sFlt-1 [40]. Human recombinant VEGF (up to 
400 g/kg) was injected once or twice daily subcutaneously over
a period of several hours. Treatment with exogenous VEGF121 also
reduced symptoms characteristic for PE, such as increased blood
pressure, albuminuria and kidney damage. Both studies showed
that the administration of exogenous VEGF in a mouse-and-rat
model for PE can alleviate the symptoms caused by high systemic
concentrations of sFlt-1 when applied over 8–10 days.
Extrapolating the data to human PE is difficult, because in
human beings circulating sFlt-1 concentrations are between 2 and
10 ng/ml in plasma over a 3–4-month time period, namely about
3–10 fold higher than in normal pregnancies. Reducing the sFlt-1
levels to below a given threshold by induction of complex forma-
tion with the corresponding ligand may be one therapeutic
approach. However, treatment with blocking antibodies for Flt-
1/VEGFR-1 is also a possibility and may have fewer side effects
than delivery of VEGF in patients. More important, the paracrine
and autocrine VEGF signalling required for normal vascular home-
ostasis will not be affected by this approach [41].
More recently, a second soluble receptor protein known as
sEng or CD105 having an activity as a TGF- co-receptor was
reported to be involved in the pathogenesis of PE [42]. Placental-
derived sEng is elevated in the sera of preeclamptic woman and
may correlate with disease severity. Co-administration with
AdvsFlt-1 and AdvsEng led to PE including the hemolysis, ele-
vated liver enzyme and low platelet (HELLP) syndrome and
restricted fetal growth in pregnant rats. Very recently, it was
shown that statins (HMG-CoA reductase inhibitors), a class of
lipid-lowering drugs, inhibit cytokine-mediated release of sFlt-1
and sEng [43]. Based on these findings, statins offer a logical
potential therapy and our study demonstrates that a reduction in
circulating sFlt-1 alleviates PE-like signs thus sFlt-1 appears to be
a not only a valid marker for a clinical outcome measure but
directly linked to signs of PE.
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